We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin Improves
Read MoreHide Full Article
Key Takeaways
COR reported Q1 adjusted EPS of $4.08, beating estimates, while revenue rose 5.5% year over year.
Cencora saw 5% U.S. segment revenue growth driven by GLP-1 and specialty drug demand.
COR expanded adjusted gross margin by 37 bps and raised FY26 revenue growth guidance to 7-9%.
Cencora, Inc. (COR - Free Report) reported fiscal first-quarter 2026adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate of $4.07 by 0.2%. The bottom line also improved 9.4% year over year.
GAAP EPS was $2.87, up 14.8% compared with the year-ago period’s figure.
Revenue Details
Revenues totaled $85.93 billion, up 5.5% year over year. The top line was almost in line with the Zacks Consensus Estimate.
Segmental Analysis
U.S. Healthcare Solutions
Revenues in this segment totaled $76.2 billion, up 5% on a year-over-year basis. This improvement was driven by overall market growth on increased unit volume, including improved sales of GLP-1 drugs and specialty products.
Segmental operating income totaled $831.3 million, up 21% year over year. Higher gross profit (as a result of increased product sales and the January 2025 acquisition of RCA) contributed to the upside, partly offset by increased operating expenses.
International Healthcare Solutions
This segment includes Alliance Healthcare, World Courier, Innomar and Profarma Specialty.
Revenues amounted to $7.6 billion, up 7.6% year over year. The top line increased 9.6% on a reported basis and 6.2% at constant currency (cc).
Operating income totaled $142.2 million, down 13.9% on a reported basis and 17% at cc. The decline was due to lower operating income at COR’s global specialty logistics and specialized consulting services businesses.
Margin Analysis
Cencora reported an adjusted gross profit of $3 billion, up 18.1% on a year-over-year basis. As a percentage of revenues, the adjusted gross margin was 3.48%, up 37 basis points (bps) year over year.
The company recorded an adjusted operating income of $1.1 billion, up 11.9% year over year. As a percentage of revenues, the adjusted operating margin was 1.24%, which expanded 8 bps from the year-ago quarter’s level.
COR exited the fiscal first quarter with cash and cash equivalents worth $1.75 billion compared with $4.36 billion in the previous quarter.
Net cash used in operating activities totaled $2.31 billion compared with $2.72 billion a year ago.
Dividend Update
Cencora's board of directors declared a quarterly dividend of 60 cents per share. The new dividend is payable on March 2, 2026, to shareholders of record at the close of business on Feb. 13, 2026.
FY26 Guidance Updated
The company provided its outlook for fiscal 2026 earnings and revenues.
Adjusted EPS is estimated to be in the $17.45-$17.75 range. The Zacks Consensus Estimate for the same is pegged at $17.62.
Total revenues are now projected to rise 7%-9% compared with the previous guidance of 5%-7%. Sales at the U.S. Healthcare Solutions segment and the International Healthcare Solutions segment are now also anticipated to grow in the range of 7%-9%.
Adjusted operating income is now expected to improve in the range of 11.5%-13.5% compared with previous guidance of 8-10% for fiscal 2026.
Operating income for the U.S. Healthcare Solutions segment is now expected to improve 14-16%, while the same for the International Healthcare Solutions business is estimated to improve 5-8%, reportedly as well as at cc.
Our Take
Cencora exited the fiscal first quarter on a mixed note, wherein earnings beat estimates, but revenues were in line. The company’s revenue guidance for fiscal 2026 was also above estimates. However, shares were down 5.3% in pre-market trading. In the last six-month period, COR’s shares have gained 23.2% compared with the industry’s growth of 18%. The S&P 500 Index was up 12.2% in the same time period.
Cencora delivered a solid start to fiscal 2026, supported by broad-based growth across its healthcare solutions platforms and sustained demand for specialty products, including GLP-1 therapies. Management highlighted the company’s continued role as a critical partner within the healthcare ecosystem, supported by disciplined execution and a focus on operational efficiency. While customer losses created some pressure on volumes, overall market growth and strong specialty demand helped offset these challenges.
Image Source: Zacks Investment Research
Performance in the international business reflected healthy underlying demand, particularly within European distribution, though profitability was pressured by operating dynamics in that market. Strength in the global specialty logistics business provided a partial offset, highlighting the benefits of Cencora’s diversified international footprint. On a constant-currency basis, growth trends remained stable, reinforcing the resilience of the company’s core operations.
Strategically, Cencora remains focused on long-term value creation through targeted capital deployment. The RCA acquisition is contributing positively to operating performance and is expected to support incremental growth going forward. In addition, the company’s move to acquire the remaining equity interest in OneOncology strengthens its position in oncology-focused services and deepens relationships with physician practices. While higher operating expenses continue to weigh on margins, ongoing investments in scale, specialty capabilities, and integrated services position Cencora well for sustained growth over time.
Boston Scientific shares have lost 12% in the past six months. Estimates for the company’s fourth-quarter 2025 EPS have remained constant at 78 cents in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.36%. In the last reported quarter, it posted an earnings surprise of 5.63%.
Estimates for Phibro Animal Health’s EPS for second-quarter fiscal 2026 have remained constant at 69 cents in the past 30 days. Shares of the company have risen 50.5% in the past six months compared with the industry’s 11.1% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.77%. In the last reported quarter, it delivered an earnings surprise of 23.73%.
AtriCure shares have risen 5.2% in the past six months. Estimates for the company’s fourth-quarter 2025 loss per share have remained stable at 4 cents in the past 30 days. ATRC’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 67.06%. In the last reported quarter, it posted an earnings surprise of 90.91%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin Improves
Key Takeaways
Cencora, Inc. (COR - Free Report) reported fiscal first-quarter 2026adjusted earnings per share (EPS) of $4.08, which beat the Zacks Consensus Estimate of $4.07 by 0.2%. The bottom line also improved 9.4% year over year.
GAAP EPS was $2.87, up 14.8% compared with the year-ago period’s figure.
Revenue Details
Revenues totaled $85.93 billion, up 5.5% year over year. The top line was almost in line with the Zacks Consensus Estimate.
Segmental Analysis
U.S. Healthcare Solutions
Revenues in this segment totaled $76.2 billion, up 5% on a year-over-year basis. This improvement was driven by overall market growth on increased unit volume, including improved sales of GLP-1 drugs and specialty products.
Segmental operating income totaled $831.3 million, up 21% year over year. Higher gross profit (as a result of increased product sales and the January 2025 acquisition of RCA) contributed to the upside, partly offset by increased operating expenses.
International Healthcare Solutions
This segment includes Alliance Healthcare, World Courier, Innomar and Profarma Specialty.
Revenues amounted to $7.6 billion, up 7.6% year over year. The top line increased 9.6% on a reported basis and 6.2% at constant currency (cc).
Operating income totaled $142.2 million, down 13.9% on a reported basis and 17% at cc. The decline was due to lower operating income at COR’s global specialty logistics and specialized consulting services businesses.
Margin Analysis
Cencora reported an adjusted gross profit of $3 billion, up 18.1% on a year-over-year basis. As a percentage of revenues, the adjusted gross margin was 3.48%, up 37 basis points (bps) year over year.
The company recorded an adjusted operating income of $1.1 billion, up 11.9% year over year. As a percentage of revenues, the adjusted operating margin was 1.24%, which expanded 8 bps from the year-ago quarter’s level.
Cencora, Inc. Price, Consensus and EPS Surprise
Cencora, Inc. price-consensus-eps-surprise-chart | Cencora, Inc. Quote
Financial Update
COR exited the fiscal first quarter with cash and cash equivalents worth $1.75 billion compared with $4.36 billion in the previous quarter.
Net cash used in operating activities totaled $2.31 billion compared with $2.72 billion a year ago.
Dividend Update
Cencora's board of directors declared a quarterly dividend of 60 cents per share. The new dividend is payable on March 2, 2026, to shareholders of record at the close of business on Feb. 13, 2026.
FY26 Guidance Updated
The company provided its outlook for fiscal 2026 earnings and revenues.
Adjusted EPS is estimated to be in the $17.45-$17.75 range. The Zacks Consensus Estimate for the same is pegged at $17.62.
Total revenues are now projected to rise 7%-9% compared with the previous guidance of 5%-7%. Sales at the U.S. Healthcare Solutions segment and the International Healthcare Solutions segment are now also anticipated to grow in the range of 7%-9%.
Adjusted operating income is now expected to improve in the range of 11.5%-13.5% compared with previous guidance of 8-10% for fiscal 2026.
Operating income for the U.S. Healthcare Solutions segment is now expected to improve 14-16%, while the same for the International Healthcare Solutions business is estimated to improve 5-8%, reportedly as well as at cc.
Our Take
Cencora exited the fiscal first quarter on a mixed note, wherein earnings beat estimates, but revenues were in line. The company’s revenue guidance for fiscal 2026 was also above estimates. However, shares were down 5.3% in pre-market trading. In the last six-month period, COR’s shares have gained 23.2% compared with the industry’s growth of 18%. The S&P 500 Index was up 12.2% in the same time period.
Cencora delivered a solid start to fiscal 2026, supported by broad-based growth across its healthcare solutions platforms and sustained demand for specialty products, including GLP-1 therapies. Management highlighted the company’s continued role as a critical partner within the healthcare ecosystem, supported by disciplined execution and a focus on operational efficiency. While customer losses created some pressure on volumes, overall market growth and strong specialty demand helped offset these challenges.
Image Source: Zacks Investment Research
Performance in the international business reflected healthy underlying demand, particularly within European distribution, though profitability was pressured by operating dynamics in that market. Strength in the global specialty logistics business provided a partial offset, highlighting the benefits of Cencora’s diversified international footprint. On a constant-currency basis, growth trends remained stable, reinforcing the resilience of the company’s core operations.
Strategically, Cencora remains focused on long-term value creation through targeted capital deployment. The RCA acquisition is contributing positively to operating performance and is expected to support incremental growth going forward. In addition, the company’s move to acquire the remaining equity interest in OneOncology strengthens its position in oncology-focused services and deepens relationships with physician practices. While higher operating expenses continue to weigh on margins, ongoing investments in scale, specialty capabilities, and integrated services position Cencora well for sustained growth over time.
COR’s Zacks Rank & Stocks to Consider
COR carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , Phibro Animal Health (PAHC - Free Report) and AtriCure (ATRC - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific shares have lost 12% in the past six months. Estimates for the company’s fourth-quarter 2025 EPS have remained constant at 78 cents in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.36%. In the last reported quarter, it posted an earnings surprise of 5.63%.
Estimates for Phibro Animal Health’s EPS for second-quarter fiscal 2026 have remained constant at 69 cents in the past 30 days. Shares of the company have risen 50.5% in the past six months compared with the industry’s 11.1% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.77%. In the last reported quarter, it delivered an earnings surprise of 23.73%.
AtriCure shares have risen 5.2% in the past six months. Estimates for the company’s fourth-quarter 2025 loss per share have remained stable at 4 cents in the past 30 days. ATRC’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 67.06%. In the last reported quarter, it posted an earnings surprise of 90.91%.